So-Young International Business Summary

So-Young International Inc. (SY) operates China’s leading platform for medical aesthetics, transitioning from a pure-play digital marketplace to a vertically integrated hybrid model. The company generates revenue through three primary segments: Information Services (advertising and content fees from service providers), Reservation Services (transaction-based commissions on bookings), and its rapidly expanding Aesthetic Treatment Services, which now constitutes nearly half of total revenue through a network of over 40 branded offline centers. This strategic pivot focuses on high-growth, direct-to-consumer clinical services and upstream supply chain integration, including the distribution of medical equipment and injectables. In the competitive landscape, So-Young maintains a specialized niche against diversified giants like Meituan and Ping An Healthcare and Technology, while competing for user engagement with content-driven platforms such as Zhihu. Unlike its broader peers, So-Young’s market position is defined by its deep vertical integration and a closed-loop ecosystem that spans from social community discovery to physical treatment delivery. Leadership is anchored by Co-founder, Chairman, and CEO Xing Jin, a veteran of China’s internet sector with prior leadership roles at Tencent’s Tenpay and IM2.0 Interactive Group. The executive team was significantly bolstered in early 2025 with the appointments of Chief Operating Officer Gefei Li, formerly a global associate partner at McKinsey & Company, and Chief Technology Officer Xiaodong Ying, who oversees the platform’s digital infrastructure. Founding member Bei Wang continues to serve as Chief Marketing Officer, leveraging her extensive background in journalism and brand marketing to drive the platform’s content-centric community. The company is backed by prominent institutional investors, including Orchid Asia Group, Matrix Partners China, and Jingwei Venture Capital, with CEO Xing Jin maintaining controlling voting power through a dual-class share structure. The board includes seasoned independent directors such as Dr. Haipeng Zhang and Nan Shen, the CFO of Gaotu Techedu, providing robust corporate governance as the firm scales its offline clinical footprint.